Tamoxifen: catalyst for the change to targeted therapy.

[1]  B. O’Malley,et al.  Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  V. Jordan,et al.  Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices—Point , 2007, Cancer Epidemiology Biomarkers & Prevention.

[3]  V. Jordan.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer , 2007, Steroids.

[4]  J. Bolton,et al.  Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. , 2007, Journal of medicinal chemistry.

[5]  J. Cuzick,et al.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.

[6]  T. Powles,et al.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. , 2007, Journal of the National Cancer Institute.

[7]  V. Jordan.  Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial. , 2006, European journal of cancer.

[8]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[9]  Nareshkumar Jain,et al.  Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness. , 2006, Journal of medicinal chemistry.

[10]  Rong Zhou,et al.  Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. , 2006, Journal of medicinal chemistry.

[11]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[12]  V. Jordan,et al.  Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer , 2006, British journal of pharmacology.

[13]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[15]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[16]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[17]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[18]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[19]  A. Vessières,et al.  Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior. , 2005, Journal of medicinal chemistry.

[20]  M. Follettie,et al.  The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-κB transcriptional activity in models of rheumatoid arthritis , 2005, Arthritis research & therapy.

[21]  M. Geiser,et al.  Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands. , 2005, Journal of medicinal chemistry.

[22]  J. Keith,et al.  Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. , 2004, Journal of medicinal chemistry.

[23]  Ann-Gerd Thorsell,et al.  Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators. , 2004, Journal of medicinal chemistry.

[24]  E. Perez,et al.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.

[25]  B. Fournier,et al.  Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands. , 2003, Journal of medicinal chemistry.

[26]  V. Jordan,et al.  Tamoxifen: a most unlikely pioneering medicine , 2003, Nature Reviews Drug Discovery.

[27]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[28]  V. Jordan,et al.  Selective Estrogen Receptor Modulation : A Personal Perspective 1 , 2001 .

[29]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[30]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[31]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[32]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[33]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[34]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[35]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[36]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[37]  V. Jordan,et al.  Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. , 1990, Cancer research.

[38]  T. Powles,et al.  A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. , 1989, British Journal of Cancer.

[39]  R. Peto,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. , 1989, The New England journal of medicine.

[40]  V. Jordan,et al.  The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole , 1988, Breast Cancer Research and Treatment.

[41]  S. Robinson,et al.  Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.

[42]  J. Lindgren,et al.  Effects of anti-estrogens on bone in castrated and intact female rats , 1987, Breast Cancer Research and Treatment.

[43]  V. Jordan,et al.  Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. , 1987, Cancer research.

[44]  ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh , 1987, The Lancet.

[45]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[46]  G. Ribeiro,et al.  The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma--7-yr results. , 1985, European journal of cancer & clinical oncology.

[47]  B. Rasmussen,et al.  BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES , 1985, The Lancet.

[48]  RANDOMISED TRIAL OF CHEMO-ENDOCRINE THERAPY, ENDOCRINE THERAPY, AND MASTECTOMY ALONE IN POSTMENOPAUSAL PATIENTS WITH OPERABLE BREAST CANCER AND AXILLARY NODE METASTASIS Ludwig Breast Cancer Study Group , 1984, The Lancet.

[49]  Michael Baum,et al.  IMPROVED SURVIVAL AMONGST PATIENTS TREATED WITH ADJUVANT TAMOXIFEN AFTER MASTECTOMY FOR EARLY BREAST CANCER , 1983, The Lancet.

[50]  M. Palmer,et al.  Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. , 1983, British medical journal.

[51]  M. Baum,et al.  CONTROLLED TRIAL OF TAMOXIFEN AS ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST CANCER Interim Analysis at Four Years by Nolvadex Adjuvant Trial Organisation , 1983, The Lancet.

[52]  V. Jordan,et al.  Pharmacology of tamoxifen in laboratory animals. , 1980, Cancer treatment reports.

[53]  V. Jordan,et al.  Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. , 1980, European journal of cancer.

[54]  V. Jordan,et al.  EVIDENCE FOR THE METABOLIC ACTIVATION OF NON‐STEROIDAL ANTIOESTROGENS: A STUDY OF STRUCTURE‐ACTIVITY RELATIONSHIPS , 1980, British journal of pharmacology.

[55]  D. Kiang,et al.  Tamoxifen (antiestrogen) therapy in advanced breast cancer. , 1977, Annals of internal medicine.

[56]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.

[57]  V. Jordan,et al.  Binding of [3h]tamoxifen in rat uterine cytosols: A comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis , 1977, Molecular and Cellular Endocrinology.

[58]  V. Jordan,et al.  Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat , 1977, Molecular and Cellular Endocrinology.

[59]  K. Griffiths,et al.  Effects of oestradiol-17β and tamoxifen on nuclear oestradiol-17β receptors in DMBA-induced rat mammary tumours , 1977 .

[60]  S. Legha,et al.  Nafoxidine–‐an antiestrogen for the treatment of breast cancer , 1976, Cancer.

[61]  V. Jordan.  Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. , 1976, Cancer treatment reports.

[62]  K. Griffiths,et al.  Effects of oestradiol - 17beta and tamoxifen on total and accessible cytoplasmic oestradiol - 17beta receptors in DMBA-induced rat mammary tumours. , 1976, European journal of cancer.

[63]  V. Jordan.  Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. , 1976, European journal of cancer.

[64]  V. Jordan,et al.  Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response. , 1976, The Journal of endocrinology.

[65]  G. Bonadonna,et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.

[66]  V. Jordan,et al.  Tamoxifen as an anti-tumour agent: effect on oestrogen binding. , 1976, The Journal of endocrinology.

[67]  V. Jordan,et al.  Tamoxifen as an anti-tumour agent: role of oestradiol and prolactin. , 1976, The Journal of endocrinology.

[68]  M. Lippman,et al.  Oestrogen-responsive human breast cancer in long term tissue culture , 1975, Nature.

[69]  R. Nicholson,et al.  The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. , 1975, European journal of cancer.

[70]  V. Jordan,et al.  Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. , 1975, European journal of cancer.

[71]  C. Redmond,et al.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.

[72]  V. Jordan.  243. Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)—induced rat mammary carcinoma model , 1974 .

[73]  H. Ward.  Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels , 1973, British medical journal.

[74]  I. Todd,et al.  A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.

[75]  L. Terenius.  Anti-oestrogens and breast cancer. , 1971, European journal of cancer.

[76]  L. Terenius.  Effect of anti-oestrogens on initiation of mammary cancer in the female rat. , 1971, European journal of cancer.

[77]  A. Klopper,et al.  Medazepam Compared with Amylobarbitone in Treatment of Anxiety , 1971, British medical journal.

[78]  P. Pujol-Amat,et al.  Induction of ovulation with clomiphene citrate. , 1969, Bulletin de la Societe royale belge de gynecologie et d'obstetrique.

[79]  J. Gorski,et al.  A receptor molecule for estrogens: studies using a cell-free system. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[80]  K.,et al.  A new derivative of triphenylethylene: effect on implantation and mode of action in rats. , 1967, Journal of reproduction and fertility.

[81]  M. Harper,et al.  Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes , 1966, Nature.

[82]  J. Gorski,et al.  A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[83]  C. Huggins,et al.  Mammary Cancer Induced by a Single Feeding of Polynuclear Hydrocarbons, and its Suppression , 1961, Nature.

[84]  L. Lerner,et al.  A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. , 1958, Endocrinology.

[85]  A. Lacassagne,et al.  Hormonal Pathogenesis of Adenocarcinoma of the Breast , 1936 .

[86]  V. Jordan.  Designer estrogens. , 1998, Scientific American.

[87]  D. Machin,et al.  Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. , 1997, Journal of the National Cancer Institute.

[88]  R. Gelber,et al.  Adjuvant Therapy of Breast Cancer IV , 1993, Recent Results in Cancer Research.

[89]  V. Jordan,et al.  Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. , 1990, European journal of cancer.

[90]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[91]  V. Jordan.  Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. , 1988, Cancer investigation.

[92]  K. McPherson,et al.  Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. , 1983, Lancet.

[93]  J. Ingle,et al.  Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. , 1981, The New England journal of medicine.

[94]  E. Wallach,et al.  Induction of ovulation with clomiphene citrate. , 1977, The Journal of reproductive medicine.

[95]  K. Griffiths,et al.  Effects of oestradiol-17beta and tamoxifen on nuclear oestradiol-17beta receptors in DMBA-induced rat mammary tumours. , 1977, European journal of cancer.

[96]  M. Harper,et al.  Mode of action of I.C.I. 46,474 in preventing implantation in rats. , 1967, Journal of Endocrinology.